In vivo testing of 177Lu-labelled anti-PSMA antibody as a new radioimmunotherapeutic agent against prostate cancer.

The goal of the present study was to test the (177)Lu-labelled anti-PSMA monoclonal antibody 3/F11 ((177)Lu-DOTA-3/F11) as a new radioimmunotherapeutic agent in a prostate cancer SCID mouse xenograft model.
The mAb 3/F11 was (177)Lu labelled using 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) as chelating agent. DOTA-3/F11 was tested for cell binding and serum immunoreactivity by flow cytometry. The biodistribution and the therapeutic efficacy of (177)Lu-DOTA-3/F11 in mice bearing PSMA-positive C4-2 prostate cancer xenografts were evaluated.
3/F11 and DOTA-3/F11 showed high and specific cell binding and similar serum half-lives of approximately seven days. Biodistribution studies revealed an increasing tumour uptake of (177)Lu DOTA-3/F11 over time with maximum tumour-to-muscle and tumour-to-blood ratios after 72 h. A single dose of 1 MBq (177)Lu-DOTA-3/F11 inhibited tumour growth and prolonged survival.
This study indicated that (177)Lu-DOTA-3/F11 may be a suitable radioimmunotherapeutic agent for the treatment of prostate cancer.
AuthorsMartin Behe, Karen Alt, Friederike Deininger, Patrick Bühler, Ulrich Wetterauer, Wolfgang A Weber, Ursula Elsässer-Beile, Philipp Wolf
JournalIn vivo (Athens, Greece) (In Vivo) 2011 Jan-Feb Vol. 25 Issue 1 Pg. 55-9 ISSN: 1791-7549 [Electronic] Greece
PMID21282735 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • 177Lu-DOTA-3-F11
  • Antibodies, Monoclonal
  • Antigens, Surface
  • Coordination Complexes
  • Radioisotopes
  • Lutetium
  • Glutamate Carboxypeptidase II
  • glutamate carboxypeptidase II, human
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Antigens, Surface (immunology)
  • Cell Line, Tumor
  • Coordination Complexes (therapeutic use)
  • Glutamate Carboxypeptidase II (immunology)
  • Humans
  • Isotope Labeling
  • Lutetium (therapeutic use)
  • Male
  • Mice
  • Mice, SCID
  • Prostatic Neoplasms (radiotherapy)
  • Radioimmunotherapy (methods)
  • Radioisotopes
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: